S.R. BATLIBOI & CO. LLP
Chartered Accountants

Golf View Corporate Tower-B
Sector-42, Sector Road
Gurgaon-122 002, Haryana, India
Tel : +91 124 464 4000
Fax : +91 124 464 4050

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Clause 41 of the Listing Agreement

To
Board of Directors of
Fortis Healthcare Limited

1. We have audited the quarterly financial results of Fortis Healthcare Limited ('the Company') for the quarter ended March 31, 2015 and the financial results for the year ended March 31, 2015, attached herewith, being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2015 and the published year-to-date figures up to December 31, 2014, being the date of the end of the third quarter of the current financial year, which were subjected to limited review. The financial results for the quarter ended March 31, 2015 have been prepared on the basis of the financial results for the nine-month period ended December 31, 2014, the audited annual financial statements as at and for the year ended March 31, 2015, and the relevant requirements of Clause 41 of the Listing Agreement and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these financial results based on our review of the financial results for the nine-month period ended December 31, 2014 which was prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, notified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended March 31, 2015; and the relevant requirements of Clause 41 of the Listing Agreement.

2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

3. In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date results:

    i. are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
    ii. give a true and fair view of the net loss and other financial information for the quarter ended March 31, 2015 and net loss and other financial information for the year ended March 31, 2015.

4. Further, read with paragraph 1 above, we report that the figures for the quarter ended March 31, 2015 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2015 and the published year-to-date figures up to December 31, 2014, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated in paragraph 1 above, as required under Clause 41(I)(d) of the Listing Agreement.

S.R. BATLIBOI & CO. LLP GURGAON

5. Further, read with paragraph 1 above, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For S.R. Batliboi & Co. LLP
Chartered Accountants
ICAI Firm registration number: 301003E

per Tridibes Basu
Partner
Membership No.: 017401

Place of Signature: Gurgaon
Date: May 28, 2015

S.R. BATLIBOI & CO. LLP
GURGAON

S.R. BATLIBOI & CO. LLP
Chartered Accountants

Golf View Corporate Tower-B
Sector-42, Sector Road
Gurgaon-122 002, Haryana, India
Tel : +91 124 464 4000
Fax : +91 124 464 4050

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Clause 41 of the Listing Agreement

To
Board of Directors of
Fortis Healthcare Limited

1. We have audited the quarterly consolidated financial results of Fortis Group comprising of Fortis Healthcare Limited ('the Company'), its subsidiaries, joint ventures and associates (together, 'the Fortis Group') for the quarter ended March 31, 2015 and the consolidated financial results for the year ended March 31, 2015, attached herewith, being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The quarterly consolidated financial results are the derived figures between the audited figures in respect of the year ended March 31, 2015 and the published year-to-date figures up to December 31, 2014, being the date of the end of the third quarter of the current financial year, which were subjected to limited review. The consolidated financial results for the quarter ended March 31, 2015 have been prepared on the basis of the consolidated financial results for the nine-month period ended December 31, 2014, the audited annual consolidated financial statements as at and for the year ended March 31, 2015, and the relevant requirements of Clause 41 of the Listing Agreement and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these consolidated financial results based on our audit of the consolidated financial results for the nine-month period ended December 31, 2014 which was prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, notified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India; our audit of the annual consolidated financial statements as at and for the year ended March 31, 2015; and the relevant requirements of Clause 41 of the Listing Agreement.

2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

3. a) We did not audit the financial information of certain overseas subsidiaries whose financial information, prepared under either International Financial Reporting Standards ('IFRS') or Singapore Financial Reporting Standards ('SFRS'), as the case may be, whose financial statements reflect total assets of Rs. 198,443.79 lacs as at March 31, 2015, total revenues of Rs. 21,736.33 lacs for the year ended March 31, 2015 and Rs 4,736.46 lacs for the quarter ended March 31, 2015, as well as the net cash outflows of Rs. 97,392.43 lacs for the year ended March 31, 2015. This financial information of these subsidiaries have prepared in accordance with IFRS or SFRS and have been audited by other auditors who have submitted their audit opinions, prepared under generally accepted auditing standards of their respective countries, to the management of the respective companies, copies of which have been provided to us by the Company. Further, we also did not audit the financial information of certain overseas associates whose financial information, prepared under International Financial Reporting Standards ('IFRS'), in the aggregate reflect net profit of Rs. 232.10 lacs and Rs. 29.18 lacs, for the year ended March 31, 2015 and for the quarter ended March 31, 2015, respectively being the proportionate share of Fortis group. This financial information has been prepared by the management, and our opinion is based solely on the management certified accounts. The management of the Company has converted this audited financial information of the Company's

S.R. BATLIBOI & CO. LLP GURGAON

subsidiaries and associates to accounting principles generally accepted in India, for the purpose of preparation of the Company's consolidated financial statements under accounting principles generally accepted in India. Our opinion, thus insofar it relates to amounts included in respect of these subsidiaries and associates, is based solely on the reports of other auditors or management certified accounts under the accounting policies generally accepted in respective countries and the aforesaid conversion undertaken by management, which has been examined by us on a test basis. Our opinion is not qualified in respect of this matter.

b) We did not audit the financial information of certain subsidiaries, whose financial information prepared under the generally accepted accounting principles accepted in India, whose financial statements reflect total assets of Rs. 219,515.62 lacs as at March 31 2015, total revenues of Rs. 23,470.82 lacs for the year ended March 31, 2015 and Rs. 5,862.14 lacs for the quarter ended March 31, 2015, as well as the net cash outflows of Rs. 99,171.99 lacs for the year ended March 31, 2015. This financial information has been audited by other auditors whose reports have been furnished to us, and our opinion is based solely on the report of other auditors. Our opinion is not qualified in respect of this matter.

c) We did not audit the financial information of certain joint ventures, whose financial statements reflect total assets of Rs. 2,371.24 lacs as at March 31, 2015, total revenues of Rs. 4,138.89 lacs for the year ended March 31, 2015 and Rs. 1,046.04 lacs for the quarter ended March 31, 2015, as well as the gross cash flow of Rs. 819.27 lacs for the year ended March 31, 2015, being the proportionate share of Fortis Group, for the year then ended. This financial information has been audited by other auditors whose reports have been furnished to us, and our opinion is based solely on the report of other auditors. Our opinion is not qualified in respect of this matter.

d) We did not audit the financial information of certain associates, whose financial information reflect net profit of Rs. 232.10 lacs and Rs. 29.18 lacs for the year ended March 31, 2015 and for the quarter ended March 31, 2015, respectively, being the proportionate share of Fortis Group, for the year ended March 31, 2015. This financial information has been prepared by the management, and our opinion is based solely on the management certified accounts. Our opinion is not qualified in respect of this matter.

4. Attention is drawn to notes 6A(a) and 6A(b) to the financial results, regarding matters relating to tax demands and termination of certain land leases allotted by Delhi Development Authority (DDA), respectively against one of the subsidiary ("Escorts Heart Institute and Research Centre Limited") more fully described therein. Based on the advice given by the external legal counsel, no provision /adjustment has been considered necessary by the Group in this regard in the consolidated financial results. Our opinion is not qualified in respect of the aforesaid matters.

5. Attention is drawn to note 6A(c) to the financial results, regarding non-compliance with order of Honorable High Court of Delhi in relation to provision of free treatment/beds to poor by one of the subsidiaries ("Escorts Heart Institute Research Centre Limited"), more fully described therein. Based on legal opinion, no provision/ adjustment has been considered necessary by the Group in this regard in the consolidated financial results. Our opinion is not qualified in respect of the aforesaid matter.

6. Attention is drawn to note 6B to the financial results, relating to the order of Navi Mumbai Municipal Corporation (NMMC) received by one of the subsidiary ("Hiranandani Healthcare Private Limited"), concerning alleged contravention of the provisions of Bombay Nursing Home Registration (Amended) Act, 2005 and more fully described therein. Based on the advice given by the external legal counsel, no provision/ adjustment has been considered necessary by the Company in this regard in the financial results. Our opinion is not qualified in respect of the aforesaid matter.

S.R. BATLIBOI & CO. LLP * GURGAON *

7. In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

    i. are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
    ii. give a true and fair view of the net loss and other financial information for the quarter ended March 31, 2015 and net loss and other financial information for the year ended March 31, 2015.

8. Further, read with paragraph 1 above, we report that the figures for the quarter ended March 31, 2015 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2015 and the published year-to-date figures up to December 31, 2014, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated in paragraph 1 above, as required under Clause 41(I)(d) of the Listing Agreement.

9. Further, read with paragraph 1 above, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For S.R. Batliboi & Co. LLP
Chartered Accountants
ICAI Firm registration number: 301003E

per Tridibes Basu
Partner
Membership No.: 017401

S.R. BATLIBOI & CO. LLP * GURGAON *

Place of Signature: Gurgaon
Date: May 28, 2015

FORTIS HEALTHCARE LIMITED
STATEMENT OF AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2015

Part I

(₹ in lacs)

Particulars	Consolidated					Standalone				
	Quarter ended			Year ended		Quarter ended			Year ended	
	March 31, 2015	December 31, 2014	March 31, 2014	March 31, 2015	March 31, 2014	March 31, 2015	December 31, 2014	March 31, 2014	March 31, 2015	March 31, 2014
	(Audited) (Refer note 2)	(Unaudited)	(Audited) (Refer note 2)	(Audited)	(Audited)	(Audited) (Refer note 2)	(Unaudited)	(Audited) (Refer note 2)	(Audited)	(Audited)
1. Income from operations	104,946	101,181	92,808	408,863	470,183	15,145	14,373	9,015	59,578	35,407
2. Other operating income	1,427	1,272	1,264	5,150	5,747	287	395	433	1,486	1,483
3. Total income	**106,373**	**102,453**	**94,072**	**414,013**	**475,930**	**15,432**	**14,768**	**9,448**	**61,064**	**36,890**
4. Expenditure										
(a) Cost of material consumed	23,577	23,005	23,022	94,933	100,784	3,577	3,481	2,596	14,730	10,833
(b) Employees benefit expenses	20,169	21,545	19,222	84,207	123,073	4,340	4,737	3,772	18,245	13,604
(c) Other expenditure	58,491	54,531	54,912	221,495	233,733	11,185	10,679	7,212	42,957	20,496
(d) Total	**102,237**	**99,081**	**97,156**	**400,635**	**457,590**	**19,102**	**18,897**	**13,580**	**75,932**	**44,933**
5. Profit (+)/ Loss (-) from operations before other income & finance costs, depreciation and amortisation (3-4)	**4,136**	**3,372**	**(3,084)**	**13,378**	**18,340**	**(3,670)**	**(4,129)**	**(4,132)**	**(14,868)**	**(8,043)**
6. Other income	3,507	3,884	4,356	9,874	17,059	5,482	5,522	5,293	21,791	22,964
7. Exceptional gain (refer note 7)	-	-	-	33	35,334	-	-	-	265	-
8. Profit from operations before finance costs, depreciation and amortisation (5+6+7) (EBITDA)	**7,643**	**7,256**	**1,272**	**23,285**	**70,733**	**1,812**	**1,393**	**1,161**	**7,188**	**14,921**
9. Net depreciation/ impairment & amortization expenses	6,097	7,462	5,345	26,279	24,786	622	532	366	2,713	1,700
10. Profit (+)/ Loss (-) from operations before finance costs (8-9)	**1,546**	**(206)**	**(4,073)**	**(2,994)**	**45,947**	**1,190**	**861**	**795**	**4,475**	**13,221**
11. Finance costs	3,730	3,866	2,764	15,334	31,633	1,863	2,073	2,057	8,063	9,078
12. Profit (+)/ Loss (-) from operations before tax (10-11) (including profit attributable to	**(2,184)**	**(4,072)**	**(6,837)**	**(18,328)**	**14,314**	**(673)**	**(1,212)**	**(1,262)**	**(3,588)**	**4,14[illegible]**

Fortis Healthcare New Delhi

S.R. BATLIBOI & CO. LLP GURGAON

discontinuing operations, refer note 8)										
13. Tax expense (refer note 10)	398	(187)	1,140	626	2,650	-	(217)	(90)	(197)	1,744
14. Net Profit (+)/ Loss (-) from ordinary activities after tax (12-13)	**(2,582)**	**(3,885)**	**(7,977)**	**(18,954)**	**11,664**	**(673)**	**(995)**	**(1,172)**	**(3,391)**	**2,399**
15. Less : Minority Interest in profit / (loss)	541	(61)	(6)	1,374	496	-	-	-	-	-
16. Add : Share in profit of associate companies	1,370	1,596	240	5,958	1,086	-	-	-	-	-
17. Net Profit (+)/ Loss (-) after taxes, minority interest and share of profit of associates (14-15+16)	**(1,753)**	**(2,228)**	**(7,731)**	**(14,370)**	**12,254**	**(673)**	**(995)**	**(1,172)**	**(3,391)**	**2,399**
18. Paid-up equity share capital (Face Value Rs. 10 per Share)	46,281	46,279	46,279	46,281	46,279	46,281	46,279	46,279	46,281	46,279
19. Reserves excluding revaluation reserves				358,482	381,956				321,671	324,679
20.Earnings Per Share (excluding exceptional items) :- Basic	(0.38)	(0.48)	(1.71)	(3.11)	(5.09)	(0.15)	(0.21)	(0.26)	(0.79)	0.53
:- Diluted	(0.38)	(0.48)	(1.71)	(3.11)	(5.09)	(0.15)	(0.21)	(0.26)	(0.79)	0.53
Part II										
A. Particulars of Shareholding										
1. Public shareholding - No of Shares	132,651,466	132,634,966	132,632,366	132,651,466	132,632,366	132,651,466	132,634,966	132,632,366	132,651,466	132,632,366
- Percentage of shareholding	28.66%	28.66%	28.66%	28.66%	28.66%	28.66%	28.66%	28.66%	28.66%	28.66%
2. Promoters and promoter group Shareholding										
a) Pledged/ Encumbered - No of Shares	246,853,635	272,532,750	229,777,900	246,853,635	229,777,900	246,853,635	272,532,750	229,777,900	246,853,635	229,777,900
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	74.77%	82.55%	69.60%	74.77%	69.60%	74.77%	82.55%	69.60%	74.77%	69.60%
- Percentage of shares (as a % of the total share capital of the company)	53.34%	58.89%	49.65%	53.34%	49.65%	53.34%	58.89%	49.65%	53.34%	49.65%
b) Non-encumbered - No of Shares	83,300,313	57,621,198	100,376,048	83,300,313	100,376,048	83,300,313	57,621,198	100,376,048	83,300,313	100,376,048

Fortis Health... New Delhi

S.R. Batliboi & Co. LLP * Gurgaon *

- Percentage of shares (as a % of total shareholding of promoter and promoter group)	25.23%	17.45%	30.40%	25.23%	30.40%	25.23%	17.45%	30.40%	25.23%	30.40%
- Percentage of shares (as a % of the total share capital of the company)	18.00%	12.45%	21.69%	18.00%	21.69%	18.00%	12.45%	21.69%	18.00%	21.69%
B. Investor Complaints										
Pending at the beginning of the quarter	-									
Received during the quarter	4									
Disposed off during the quarter	4									
Remaining unsolved at the end of the quarter	-									

Notes to the results

1. The above audited financial results for the year ended March 31, 2015 have been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their respective meetings held on May 27, 2015 and May 28, 2015.

2. The figures for the quarter ended March 31, 2015 and March 31, 2014 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2015 and March 31, 2014 respectively and the unaudited published year to date figures up to December 31, 2014 and December 31, 2013 respectively, being the end of the third quarter of the respective financial years, which were subjected to a limited review.

3. **Segment Reporting**

Business segments:

The Group is primarily engaged in the business of healthcare services, which in the opinion of management is considered to be the only reportable business segment as per Accounting Standard 17 on 'Segment Reporting' notified under the Companies (Accounting Standards) Rules, 2006 as amended. Healthcare services include various patient care services delivered through clinical establishment, medical services companies, pathology and radiology services etc.

Geographical segments:

The group operates in the business segment explained above in two principal geographical areas, geographical segments being classified as secondary segment. In India, its home country, the group focuses largely on healthcare services. Additionally, the group's operations 'Outside India' are now mostly focusing on Middle East. The group primarily operates in Dubai and Mauritius.

Fortis Healthcare Ltd. New Delhi

S.R. Batliboi & Co. LLP Gurgaon

Revenue from operations –by geographical markets

The following table shows the distribution of the Company's consolidated revenues by geographical market:

(₹ in lacs)

Region	Quarter ended			Year ended	
	31-Mar-15	31-Dec-14	31-Mar-14	31-Mar-15	31-Mar-14
India	101,725	97,062	88,533	392,968	344,764
Outside India*	4,648	5,391	5,539	21,045	131,166
Total	**106,373**	**102,453**	**94,072**	**414,013**	**475,930**

* Includes revenue relating to discontinuing operations (see note 8 below).

Carrying value of Assets and additions to tangible and intangible fixed assets- by location of assets

The following table shows the carrying amount of segment assets and additions to tangible and intangible fixed assets by geographical area in which the assets are located:

(₹ in lacs)

Region	Carrying amount of Segment assets		Additions to Fixed & Intangible assets	
	31-Mar-15	31-Mar-14	31-Mar-15	31-Mar-14
India	552,032	574,557	46,329	66,276
Outside India	209,525	213,523	1,435	5,529
Total	**761,557**	**788,080**	**47,764**	**71,805**

4. Other income includes interest income, foreign exchange fluctuation gain, profit on sale of assets, profit on sale of investments, forward cover premium amortization and miscellaneous income, whichever is relevant for the period.

Fortis Healthcare Ltd. New Delhi

S.R. Batliboi & Co. LLP Gurgaon

5. Statement of Assets and Liabilities :

(₹ in lacs)

	Particulars	Consolidated		Standalone	
		As at March 31, 2015	As at March 31, 2014	As at March 31, 2015	As at March 31, 2014
A	**EQUITY AND LIABILITIES**				
1	**Shareholders' funds**				
	(a) Share capital	46,281	46,279	46,281	46,279
	(b) Reserves and surplus	358,482	381,956	321,671	324,679
	Sub-total - Shareholders' funds	**404,763**	**428,235**	**367,952**	**370,958**
2	Minority interest	15,294	13,926	-	-
3	Compulsorily convertible preference shares issued by subsidiaries	67,000	67,000	-	-
4	**Non-current liabilities**				
	(a) Long-term borrowings	100,668	165,868	59,733	125,166
	(b) Deferred tax liabilities (net)	2,388	6,511	-	-
	(c) Other long-term liabilities	6,760	4,964	2,336	3,343
	(d) Long-term provisions	5,017	4,415	1,141	809
	Sub-total - Non-current liabilities	**114,833**	**181,758**	**63,210**	**129,318**
5	**Current liabilities**				
	(a) Short-term borrowings	2,699	3,184	-	-
	(b) Trade payables	52,508	48,172	9,693	5,102
	(c) Other current liabilities	98,531	41,231	73,844	9,655
	(d) Short-term provisions	5,929	4,574	1,222	919
	Sub-total - Current liabilities	**159,667**	**97,161**	**84,759**	**15,676**
	TOTAL - EQUITY AND LIABILITIES	**761,557**	**788,080**	**515,921**	**515,952**
B	**ASSETS**				
1	**Non-current assets**				
	(a) Fixed assets	205,920	199,499	32,619	26,750

	(b) Goodwill on consolidation	189,574	180,797	-	-
	(c) Goodwill on acquisition	49,092	49,092	3,293	-
	(d) Non-current investments	84,768	82,397	210,273	210,268
	(e) Deferred tax assets (net)	3,099	3,010	-	20
	(f) Long-term loans and advances	57,497	68,354	64,091	59,322
	(g) Other non-current assets	2,675	891	5,700	2,379
	Sub-total - Non-current assets	**592,625**	**584,040**	**315,976**	**298,739**
2	**Current assets**				
	(a) Current investments	61,582	99,341	30,840	69,246
	(b) Inventories	6,397	6,198	724	472
	(c) Trade receivables	42,889	44,074	10,506	8,729
	(d) Cash and cash equivalents	19,400	25,854	629	2,629
	(e) Short-term loans and advances	31,272	22,286	136,006	116,364
	(f) Other current assets	7,392	6,287	21,240	19,773
	Sub-total - Current assets	**168,932**	**204,040**	**199,945**	**217,213**
	TOTAL – ASSETS	**761,557**	**788,080**	**515,921**	**515,952**

6. A) In case of one of the subsidiary ("Escorts Heart Institute and Research Centre Limited"), that was formed after amalgamation of Escorts Heart Institute and Research Centre ('EHIRC'), Delhi Society with EHIRC, Chandigarh Society and thereafter registration of EHIRC, Chandigarh Society as a company:

a) Delhi Development Authority ('DDA') had terminated the lease deeds and allotment letters relating to land parcels on which hospital of one of the subsidiary company exists. Consequent to termination DDA issued show cause notice and initiated eviction proceedings against the subsidiary company. Both these matters are currently pending in various courts of law. Based on the experts' opinions, management is confident that subsidiary company will be able to suitably defend the termination order and eviction proceedings and accordingly considers that no adjustments are required to the financial result.

b) Further, the subsidiary company also had open tax demands of ₹ 7,870 lacs (after adjusting ₹ 3,935 lacs for which the Company has a legal right to claim from erstwhile promoters and ₹ 11,164 lacs of an escrow account which was maintained out of sale consideration payable by the Company to the erstwhile promoters) for relevant assessment years. During the current quarter, the Commissioner of Income Tax (Appeals) decided the case in favour of the subsidiary company.

c) In relation to the order of honorable High Court of Delhi relating to provision of free treatment/ beds to poor, Directorate of Health Services, Government of NCT of Delhi, (DHS) appointed a firm to calculate "unwarranted profits" arising to it due to non-compliance. The special committee of DHS stated that before giving a formal hearing to the hospital, a formal intimation shall be given regarding the recoverable amount as per calculation of the appointed firm, which as per their method of calculations amounts to ₹ 73,266 lacs, seeking hospital's comments and inputs if any. The company has responded to such intimation explaining errors and objections to the calculations and is awaiting a formal hearing in the matter with the DHS. Based on its internal assessment and advice from its counsels on the basis of the documents available, management of the group believes that it is in compliance of conditions of free treatment and free beds to the poor and does not anticipate any liability after proper hearing with DHS. No notice of hearing has since been received till date.

B) One of the subsidiary, ("Hiranandani Healthcare Private Limited"), had received an Order from Navi Mumbai Municipal Corporation (NMMC) under Bombay Nursing Home Registration Act, 1949, for certain alleged contravention of the provisions of the Act and to cancel the registration of the Hospital and immediately cease its operations. The subsidiary filed writ petition with Bombay High Court (HC) that it is ultra vires and contrary to principles of Natural Justice. HC stayed the order and restrained NMMC from taking any steps to interfere or obstruct the functioning. Despite above order, NMMC again issued another Order to submit original certificate of registration of the subsidiary. The subsidiary has filed civil application in the Writ Petition seeking leave of HC to amend the Writ Petition to include grounds of challenging the new Order as well which are pending before the HC. As per advice obtained from external legal counsel, the subsidiary has very good case to contend and the Orders are out to be set aside.

7. Exceptional items included in the above consolidated financial results includes:

(₹ in lacs)

Particulars	Quarter ended			Year ended	
	31-March-2015	31-December-2014	31-March-2014	31-March-2015	31-March-2014
a) Loss on dilution of stake in Religare Health Trust ("RHT")	-	-	-	-	(513)
b) Gain on dilution of stake in Dental Corporation Holdings Limited ("DC") [Refer note 8 (a)]	-	-	-	-	961
c) Realized foreign exchange fluctuation loss on settlement of loans within the group from sale proceeds of DC [Refer note 8 (a)]	-	-	-	-	(8,907)
d) Gain on dilution of stake in Fortis Hoan My Medical Corporation ("Hoan my") [Refer note 8 (b)]	-	-	-	-	1,377
e) Gain on dilution of stake in Quality Healthcare, Hong Kong [Refer note 8 (c)]	-	-	-	-	42,416
f) Gain on sale of net assets related to Mohali clinical establishment to Escorts Heart and Super Speciality Hospital Limited, one of the subsidiary of RHT	-	-	-	191	-
g) Loss on dissolution of partnership firm Fortis Cauvery	-	-	-	(158)	-
Net exceptional Items	-	-	-	**33**	**35,334**

Loss on dilution of stake in RHT

During year ended March 31, 2012, the Company initiated internal corporate restructuring within the Group with a view to streamline and focus Group companies' resources and energies on different divisions and undertakings and to align the business with the internationally emerging trends by moving towards innovative and cost effective methods such as transformation to asset light models. Subsequent to it RHT, a business trust established in Singapore, was listed on the Singapore Exchange Securities Trading Limited on October 19, 2012.

RHT made an offering of 567,455,000 common units at S$ 0.90 per common unit. Post the listing of RHT on Singapore Stock Exchange on October 19, 2012, the stake of Group in RHT has been diluted from 100% to 28%. Accordingly, assets and liabilities of Clinical Establishment Division held by RHT Group do not form part of the consolidated assets and liabilities of the Company w.e.f. October 19, 2012. Such deconsolidation had resulted in a net gain of ₹ 99,591 lacs (net of expenses directly incurred on the transaction) and was included as an exceptional item for the year ended March 31, 2013 and for other quarters and year ended March 31, 2014 the exceptional item is related to expenses directly incurred on the transaction.

In continuance of Group's Asset light model, during the quarter ended June 30, 2014, the Company has entered in to an agreement with Escorts Heart and Super Specialty Hospital Limited ("EHSSHL"), a subsidiary of Religare Health Trust, for transfer of net assets relating to the Mohali Clinical Establishment (in Punjab) to EHSSHL. Such transaction has resulted in net gain of ₹ 191 lacs (net of unrealised gain of ₹ 74 lacs pertaining to the Company's share in RHT) and ₹ 265 lacs in the consolidated and standalone results respectively and has been included as an exceptional item during the current year.

During the quarter ended September 30 2014, one of the subsidiary of the Company ("Fortis Cancer Care Limited" formerly known as "Fortis Health Management (South) Limited") entered into a Memorandum of Understanding (MOU) to dissolve the partnership firm, of which subsidiary Company was a partner. Accordingly, the subsidiary company's share of loss arising due to this has been shown as an exceptional item during the current year.

8. a) Discontinuing of operations relating to Dental Corporation Holdings Limited ("DC"), Australia

During the year ended March 31, 2013, Fortis Healthcare Australia Pty Limited (FHA), a wholly owned subsidiary of the Company entered into a Non-Binding Indicative offer to divest its 63.51% holding in DC to BUPA, Australia for a consideration of AUD 276 million. The deal was completed during the previous year on May 31, 2013 post approvals by the shareholders of DC, other regulatory authorities and the Supreme Court of Victoria (Australia). Accordingly, assets and liabilities of DC do not form part of the consolidated assets and liabilities of the Company w.e.f. May 31, 2013. Such deconsolidation resulted in a net gain of ₹ 961 lacs and was included as an exceptional item in the previous year ended March 31, 2014. Further, exceptional item during previous year ended March 31, 2014 also included ₹ 8,907 lacs of realized foreign exchange fluctuation loss on settlement of loans within the group from sale proceeds of DC.

The revenue and expenses in respect of the activities attributable to above discontinuing operations included in the consolidated financial results are as follows:

(₹ In lacs)

Particulars	Quarter ended			Year ended	
	March 31, 2015	December 31, 2014	March 31, 2014	March 31, 2015	March 31, 2014
Total Income	-	-	-	-	33,044
Total expenditure	-	-	-	-	34,294
Profit before tax	-	-	-	-	**(1,250)**
Tax expenses	-	-	-	-	(70)
Profit after tax	-	-	-	-	**(1,180)**

b) Discontinuing of operations relating to Fortis Hoan My Medical Corporation, Vietnam

During the quarter ended June 30, 2013, Fortis Healthcare International Pte Ltd., a subsidiary of the Company had entered into an agreement with Viva Holdings Vietnam (Pte.) Ltd, a Chandler Corporation company, to divest entire stake in Fortis Hoan My Medical Corporation (Vietnam), for a consideration of USD 80 million. The deal was completed on August 20, 2013 post receipt of all approvals. Accordingly, assets and liabilities of Hoan My do not form part of the consolidated assets and liabilities of the Company w.e.f. August 20, 2013. Such deconsolidation had resulted in a net gain of ₹ 1,377 lacs and was included as an exceptional item in the previous year ended March 31, 2014.

Fortis Healthcare Ltd. New Delhi

S.R. Batliboi & Co. LLP Gurgaon

The revenue and expenses in respect of the activities attributable to above discontinuing operations included in the consolidated financial results are as follows:

(₹ In lacs)

Particulars	Quarter ended			Year ended	
	March 31, 2015	December 31, 2014	March 31, 2014	March 31, 2015	March 31, 2014
Total Income	-	-	-	-	13,246
Total expenditure	-	-	-	-	12,036
Profit before tax	-	-	-	-	**1,210**
Tax expenses	-	-	-	-	338
Profit after tax	-	-	-	-	**872**

c) Discontinuing of operations relating to Quality Healthcare, Hong Kong

During the previous year, Fortis Healthcare International Pte Ltd. ('FHIPL'), a subsidiary of the Company entered into an agreement with BUPA International Limited to divest entire stake in Altai Investments Limited, the holding Company of Quality Healthcare, Hongkong for USD 321 million, further USD 44 million was received on account of inter group receivables net of payables. Group has received USD 365 million towards this transaction.

The deal was completed on October 24, 2013 post receipt of all approvals. Accordingly, assets and liabilities of Quality Healthcare do not form part of the consolidated assets and liabilities of the Company w.e.f. October 24, 2013. Such deconsolidation has resulted in a net gain of ₹ 42,416 lacs and has been included as an exceptional item in the previous year ended March 31, 2014. Net gain of ₹ 42,416 lacs is net of goodwill of ₹ 31,580 lacs arising on consolidation of FHIPL. In view of management, considering disposal of all significant subsidiaries of FHIPL, no goodwill is allocable to any other remaining entities.

The revenue and expenses in respect of the activities attributable to above discontinuing operations included in the consolidated financial results are as follows:

(₹ In lacs)

Particulars	Quarter ended			Year ended	
	March 31, 2015	December 31, 2014	March 31, 2014	March 31, 2015	March 31, 2014
Total Income	-	-	-	-	63,162
Total expenditure	-	-	-	-	59,212
Profit before tax	-	-	-	-	**3,950**
Tax expenses	-	-	-	-	718
Profit after tax	-	-	-	-	**3,232**

Fortis Health... New Delhi ... Ltd.

S.R. BATLIBOI & CO. LLP * GURGAON *

d) Discontinuing of operations relating to Radlink-Asia Pte Ltd., Singapore (Radlink)

Subsequent to the year ended March 31, 2015, Fortis Healthcare International Pte Ltd. (FHIPL), a wholly owned subsidiary of the Company announced its decision to divest 100% shareholding in Radlink and its subsidiaries to Fullerton Healthcare Group Pte. Limited for SGD 111 million. The transaction was concluded on May 12 2015. Since, the transaction was concluded subsequent to the year ended March 31, 2015, no effect of the same has been given in the above audited financial results.

Earlier, during the current year, Fortis Healthcare Singapore Pte Ltd. (FHS), a wholly owned subsidiary of the Company had entered into a Share Sale Agreement to divest its 100% holding in Radlink to Medi-Rad Associates Ltd, a wholly-owned subsidiary of IHH Healthcare Berhad, for SGD 137 million. However, Competition Commission of Singapore indicated that it the proposed transaction is completed as contemplated; the combination may result in lessening of competition in the relevant market in Singapore. Hence, the transaction could not be completed.

The revenue and expenses in respect of the activities attributable to above discontinuing operations included in the consolidated financial results are as follows:

(₹ In lacs)

Particulars	Quarter ended			Year ended	
	March 31, 2015	December 31, 2014	March 31, 2014	March 31, 2015	March 31, 2014
Total Income	2,973	3,368	3,638	13,546	14,358
Total expenditure	2,699	2,949	2,457	11,449	11,674
Profit before tax	**274**	**419**	**1,181**	**2,097**	**2,684**
Tax expenses	172	-	694	172	597
Profit after tax	**102**	**419**	**487**	**1,925**	**2,087**

The carrying amounts as on March 31, 2015 relating to Radlink is as follows:-

(₹ In lacs)

Particulars	31-Mar-15	31-Mar-14
Total Assets	14,419	14,563
Total Liabilities	3,751	5,382
Net Assets	**10,668**	**9,181**

e) Discontinuing of operations relating to Fortis Surgical Hospital, Singapore

During the current quarter, Fortis Healthcare International Pte Ltd. (FHIPL), a wholly owned subsidiary of the Company announced its decision to divest 100% shareholding in Fortis Healthcare Singapore Pte Ltd. which holds and operates Fortis Surgical Hospital to Concord Medical Services (International) Pte Ltd. for SGD 55 million. The transaction was concluded on April, 7 2015. Since, the transaction was concluded subsequent to the year ended March 2015, no effect of the same has been given in the above audited financial results.

Fortis Health... New Delhi

S.R. BATLIBOI & CO. LLP GURGAON

The revenue and expenses in respect of the activities attributable to above discontinuing operations included in the consolidated financial results are as follows:

(₹ In lacs)

Particulars	Quarter ended			Year ended	
	March 31, 2015	December 31, 2014	March 31, 2014	March 31, 2015	March 31, 2014
Total Income	879	944	610	4,072	4,016
Total expenditure	3,161	3,207	3,427	13,303	13,468
Profit before tax	**(2,282)**	**(2,263)**	**(2,817)**	**(9,231)**	**(9,452)**
Tax expenses	-	-	-	-	-
Profit after tax	**(2,282)**	**(2,263)**	**(2,817)**	**(9,231)**	**(9,452)**

The carrying amounts as on March 31, 2015 relating to Fortis Surgical Hospital is as follows:-

(₹ In lacs)

Particulars	31-Mar-15	31-Mar-14
Total Assets	59,808	64,510
Total Liabilities	86,331	83,084
Net Assets	**(26,523)**	**(18,574)**

9. Effective from April 1, 2014, the Company has charged depreciation based on the revised remaining useful life of the assets as per requirement of Schedule II of the Companies Act, 2013. Due to above, depreciation charge for the quarter ended March 31, 2015 and December 31, 2014 is higher by ₹ 246 lacs and ₹ 298 lacs respectively. Further, based on transitional provision provided in Note 7(b) of Schedule II, an amount of ₹ 1,291 lacs (net of deferred tax) have been adjusted with retained earnings.

10. During the quarter ended September 30, 2013, Hon'ble High Court of Delhi approved the scheme of amalgamation ('the scheme') of Fortis Health Management (North) Limited ('FHMNL') with Fortis Hospitals Limited ('FHsL'), both wholly owned subsidiaries of the Company. The scheme became effective from September 1, 2013 with appointed date as April 1, 2012. The amalgamation was done with an objective of reducing administrative cost, general overhead, managerial & other expenditure and to bring the expertise, technology & facilities under one roof. Due to this amalgamation, during the previous year ended March 31, 2014, the Company had accrued income of ₹ 4,236 lacs on account of reversal of tax expenses (₹ 2,499 lacs on account of reversal of tax expense, which is related to the year ending March 31, 2013 and ₹ 1,737 lacs on account of deferred tax credit recognized, which is related to quarter ended June 30, 2013).

11. Subsequent to the year ended March 2015, in furtherance of the agreed issue terms, the Company has redeemed on due date the outstanding USD 100 million 5% Foreign Currency Convertible Bonds(FCCBs) listed on the Luxembourg stock exchange.

Fortis Healthcare Ltd. New Delhi

S.R. BATLIBOI & CO. LLP GURGAON

12. As permitted, the Group has elected to present earnings before interest, tax, depreciation / impairment and amortisation (EBITDA) as a separate line item in its financial statements and as required by clause 41 to the listing agreement to use the classifications as per financial statement, the Group has shown the EBITDA as a separate line item in the above financial results. In its measurement, the Group does not include depreciation/impairment and amortisation expenses, finance costs and tax expenses.

13. The previous periods'/ year figures have been regrouped and recasted, wherever considered necessary.

For and on behalf of the Board of Directors

Malvinder Mohan Singh
Executive Chairman

Place: Gurgaon
Date: May 28, 2015

S.R. BATLIBOI & CO. LLP * GURGAON *

Fortis Healthcare Ltd. New Delhi

PRESS RELEASE

FORTIS FY15 CONSOLIDATED INDIA REVENUES AT RS 3928 CRS VS RS 3448 CRS (YOY)
OPERATING EBITDAC GROWS 42% (YOY)

Q4 FY15 CONSOLIDATED INDIA REVENUES AT RS 1016 CRS VS RS 885 CRS (QOQ)
OPERATING EBITDAC GROWS 91% (QOQ)

Q4 FY15 HOSPITAL BUSINESS EBITDAC GROWS 117% (QOQ)
NET DEBT TO EQUITY AT A HEALTHY 0.25x

Gurgaon, May 28, 2015: Fortis Healthcare Ltd. (Fortis), India's leading healthcare delivery Company, today, announced its consolidated results for the quarter and year ended March 31, 2015 (Q4FY15 and FY15).

India Business - Key Financial Highlights for the year (FY15)

- Consolidated India Business Revenues at Rs 3,928 Cr, up 14%.
- Consolidated India Business Operating EBITDAC (EBITDA before net business trust costs) at Rs 606 Cr, +42% and representing a 15.4% margin versus 12.4% in the previous year.
- India hospital business revenues at Rs 3,207 Cr, up 15% from FY14. Operating EBITDAC at Rs 459 Cr, a healthy growth of 48%. Operating EBITDAC represents a margin of 14.3%, up from 11.1% in FY14.
- The healthy performance in the India hospital business was a result of the all-round improvement in most of the Company's hospitals. Hospitals in the stable state group continued to show good performance. Select facilities such as FMRI (Fortis Memorial Research Institute) and FEHI (Fortis Escorts Heart Institute) witnessed significant traction during the year. The quality of the Company's revenue stream led by an improved product and payor mix also contributed positively to its performance.
- Key operational parameters in the Company's hospital business continued to see a healthy improvement. The ARPOB (Average Revenue per Occupied Bed) stood at Rs 1.26 Cr as compared to Rs 1.12 Cr in FY14, a growth of 13%. ALOS (Average length of stay) was at 3.64 days versus 3.80 days while Occupancy stood at 70% versus 73% in FY 14 respectively.
- FMRI, the Company's flagship facility which was commissioned in H1 FY14 continues to perform well. FMRI recorded revenues of Rs 350 Cr in FY15, a robust growth of 52% over the previous year. The flagship facility has become the highest ARPOB generating hospital in the Company's multi-specialty hospital network within a short span of time

with its ARPOB at Rs 2.14 Cr in FY15 (FY14: Rs 1.84 Cr). The facility has witnessed a consistent improvement in operating performance and reached EBITDAC breakeven within a record time of 5 months from the date of launch.

- The India diagnostics business recorded revenues (net of inter company elimination) of Rs 722 Cr, up 11%. The operating EBITDA was at Rs 147 Cr, up 26% and representing an EBITDA margin of 20.4% against 17.9% in FY14.

*EBITDAC refers to EBITDA before net business trust costs

India Business - Key Financial Highlights for the quarter (Q4FY15)

- Consolidated India Business Revenues at Rs 1,016 Cr, up 15%.
- Consolidated India Business Operating EBITDAC (EBITDA before net business trust costs) was at Rs 168 Cr, +91% and representing a 16.5% margin versus 9.9% in the corresponding previous quarter and 15.6% in the trailing quarter.
- India hospital business revenues at Rs 831 Cr, showed a growth of 15% over Q4FY14. Operating EBITDAC in the quarter stood at Rs 128 Cr, up significantly by 117% and representing a margin of 15.4% versus 8.2% in the corresponding previous quarter and 15.0% in the trailing quarter.
- Q4FY15 is the 4th successive quarter of margin improvement in the hospital business. Operating margins have expanded 720 bps from 8.2% in Q4FY14 to 15.4% in Q4FY15.
- ARPOB (Average Revenue per Occupied Bed) in the quarter stood at Rs 1.31 Cr as compared to Rs 1.17 Cr in Q4FY14, a growth of 12%. ALOS (Average length of stay) was at 3.66 days versus 3.79 days while Occupancy stood at 72% versus 69% in Q4 FY14 respectively.
- The India diagnostics business recorded net revenues at Rs 185 Cr, +13%. The operating EBITDA was at Rs 40 Cr, representing an EBITDA margin of 21.6% compared to 17.7% in Q4FY14.

Reported Group Financial Highlights for FY15 and Q4FY15

The reported results for FY15 are not comparable with the corresponding previous period due to progressive divestments of the Company's international businesses.

- Consolidated Group Revenues for FY15 were at Rs 4,140 Cr versus Rs 4,759 Cr for the previous year. Consolidated Group Revenues for Q4FY15 were at Rs 1,064 Cr versus Rs 941 Cr for the corresponding previous quarter.
- Consolidated PAT after Minority Interest and share in associates (PATMI) for FY15 was at Rs (144) Cr versus Rs 123 Cr in FY14. The gain recorded in FY 14 was primarily due to a one time exceptional gain arising as a result of the divestments of the Company's international assets .i.e. Quality Healthcare, Hong Kong and Hoan My, Vietnam.

Consolidated PAT after Minority Interest and share in associates (PATMI) for Q4FY15 was at Rs (18) Cr against Rs (77) Cr in Q4FY14 signifying an improvement in the Company's performance.

Commenting on the results, Mr Shivinder M Singh, Executive Vice Chairman, Fortis Healthcare Ltd, said, "With the improvement in margins for the fourth successive quarter and the overall enhancement in the operating and financial indices of our business, I believe we have set in motion a number of sustainable programs towards becoming PAT positive in the near future."

The Company divested the last of its international assets .i.e. The Fortis Surgical Hospital, Singapore and RadLink Asia, Singapore for a consideration of SGD 55 Mn and SGD 111 Mn respectively. Both these divestitures were consummated in April and May, 2015 respectively. With this the Company has successfully completed a series of divestments and used the proceeds to pare debt and further intensify its focus on the India market.

The net debt of the Company as on 31 March 2015 was at Rs 1,183 Crs, representing a net debt to equity of 0.25x times as compared to 0.17x times as on 31 March 2014. This is consistent with the Company's plans to continue to maintain a healthy balance sheet. The Company has also recently (May 21, 2015) redeemed USD 100 Mn bonds which it had issued in the year 2010. The redemption of the bonds was made from cash proceeds from the sale of the Singapore assets. This would further reduce the debt on the Company's balance sheet.

Strategic Direction

With the international divestments successfully completed, the Company strategy is firmly to enhance its focus on the India market. To this effect, the Company's emphasis would largely be on strengthening existing operations while utilizing its asset light growth strategy to expand organically and primarily through brownfield expansions. With its substantial scale and leadership position in the country, the Company expects that India, a high growth market will continue to perform well and will be the mainstay of the Company's operations for the foreseeable future.

Growth & Expansion Plans

The Company's plans for future growth are primarily based on bolt on and existing bed expansions. It has formulated an "Earn the Right to Grow Strategy" which encapsulates defined metrics for future bolt on expansion with a focus on expanding margins, adding high end medical programs and ensuring additional operational beds are margin accretive at the earliest. Such calibrated expansion would entail investment primarily by the Religare Health Trust in line with the Company's stated asset light growth strategy. The Company does not envisage any M&A in the near future and would steadfastly focus on growth and expansion by adding beds in its existing facilities across locations such as Mumbai, Amritsar, NCR, Kolkata, Jaipur, Bengaluru and Ludhiana.

Within H1FY16, two Greenfield hospitals are slated to be commissioned .i.e. Arcot Road, Chennai, a 200 bed multispecialty hospital and Sacred Heart, Bengaluru a 70 bed boutique Mother & Child facility. Both these facilities will consolidate and further strengthen the Company's presence in these key markets

Key Highlights - Hospital Business

- In FY15, the top 10 facilities contributed approx. 76% of the hospital business revenue. Most facilities, including the larger ones at Mohali, BG Road, Mulund, FMRI, Noida, Shalimar Bagh, Anandpur and Vashi, continued to show good growth momentum both in revenues and operating margins.
- A number of new medical programs and dedicated super specialty centers were commissioned in the Company's various facilities during FY 15.
    - Fortis Mohali witnessed the launch of the Fortis Cancer Institute, a 55 bed facility providing the latest available modalities in medical, surgical and radiation oncology.
    - FMRI commissioned an advanced GI physiology laboratory, becoming the only centre in North India to offer multiple new panel tests for the advanced diagnosis and treatment in Gastroenterology and Hepatobiliary sciences.
    - Fortis Malar launched India's first comprehensive centre for the management of end stage heart failure called the Fortis Centre for Heart Failure Management and Heart Transplant. It offers comprehensive heart disease management programmes that include preventive measures to avoid Heart Failure and is the largest in India.
    - The cardiac Transplant team at Fortis Malar has so far performed 45-ECMO, 41 heart-transplants, 10-VAD's and is credited with India's first successful implantation of Heartmate II LVAD and HVAD, a mechanical artificial heart pump and Inter-state heart transplant. The centre has also performed India's 1st inter-state heart transplant and the 1st pediatric heart transplant on an international patient.
    - FEHI launched a high-end, fully integrated Orthopaedics and Spine super-speciality centre, Fortis Escorts Bone & Spine Institute (FEBSI). FEBSI offers the entire spectrum of orthopaedic services, from diagnosis to treatment and rehabilitation.

Key Highlights - Diagnostics Business

- The business undertook a total of over 13.7 million accessions for Pathology and Radiology during the year, a 7% growth over FY14. SRL performed approximately 30.4 million tests in FY15 as compared to 28.7 million tests in FY14.
- Following a process of rationalization wherein it exited non-accretive laboratory practices, SRL opened 29 new laboratories while exiting 44 laboratories. It also expanded its reach by adding approximately 460 collection points and released a total of 35 new tests in FY15.
- As of 31 March 2015, SRL had 12 reference laboratories, over 250 network laboratories, over 6,400 collection points and a service portfolio of over 3,500 tests.

Board Appointments

The Board of the Company during the quarter also approved the appointments of two additional independent directors, Mr. Ravi Umesh Mehrotra and Ms. Shradha Suri Marwah. Both these appointments will add considerable width and depth to the Board of Fortis Healthcare Limited, while bringing about greater gender diversity.

Mr Ravi Umesh Mehrotra has over 25 years of experience in Financial Services, globally. He is currently associated with the Religare Group and is a Director in Religare Enterprises Ltd, Religare Health Insurance Co Ltd and, Religare Capital Markets Ltd. Prior to this, Ravi was associated with PineBridge Investments (erstwhile AIG) where he was the Global Head of Retail & Intermediary Channels.

Ms Shradha Suri Marwah is part of the Suri Group. She has over 14 years of experience and is well known for her role in taking Subros Limited, a leading auto air-conditioning systems manufacturing company, to new heights. She is recognised for her abilities in Change management, Research & Development, Human Resources, Quality and IT systems that enable decision support in organisations.

Awards and Recognitions

- Fortis Healthcare Ltd was awarded the prestigious Golden Globe Tigers Award in the 'Best Patient Safety Initiative' category for successfully adopting and implementing the World Health Organization's Surgical Safety Checklist for patient safety and risk minimisation in the operating room.
- Fortis Hospital, Bannerghatta Road, was ranked 3rd amongst the Top 20 hospitals across the globe for medical tourists in the annual ranking published by the Medical Travel Quality Alliance (MTQUA). Fortis BG Road received this recognition for the fifth year in a row, reiterating its continued commitment to the Lakshya pillar of "Patient Care."
- The Critinext initiative of Fortis Escorts Heart Institute (FEHI) was awarded the prestigious Golden Globe Tigers Award in the 'Innovation in Quality of Service Delivery' category. Critinext was selected for its innovative e-ICU model that provides intensive care beyond boundaries.
- Fortis Hospital, Bannerghatta Road, Bengaluru, received the 'Award for Managing Health At Work' from The Employer Branding Institute, in association with the World HRD Congress. The hospital won the award for the innovative HR interventions aimed at holistically addressing issues related to the physical and emotional health of all employees.

Awards to our Senior Doctors for meritorious service

- Dr Ashok Seth, Chairman of the Fortis Escorts Heart Institute (FEHI), has been conferred with the Padma Bhushan, the prestigious National award and civilian honour for his contribution in the field of Cardiac Care by the Honourable President of India. Dr Ashok Seth's contribution to the growth of Cardiology especially Interventional Cardiology has been unparalleled. Dr Seth was honoured with the Padma Shri in 2003.

- Two Fortis luminaries — Dr K. R. Balakrishnan and Dr Suresh Rao K. G. — associated with the Fortis Centre for Heart Failure & Transplant, Fortis Malar Hospital, Chennai, were recognized by the Rotary International, Tamil Nadu, Chennai, for their contributions to the field of healthcare. While Dr K. R. Balakrishnan, Director - Cardiac Sciences, was honoured with the Lifetime Achievement award, Dr Suresh Rao K. G., HOD - Cardiac Critical Care and Cardiac Anaesthesia, received the Excellence Award.

- The Cardiological Society of India's Delhi Branch conferred the Lifetime Achievement Award on Prof (Dr) Upendra Kaul, Executive Director-Cardiology & Dean, Fortis Escorts Heart Institute, New Delhi, and Fortis Flt Lt Rajan Dhall Hospital, Vasant Kunj, New Delhi.

- Several Fortis clinicians were recognised at the Worldwide Achievers Healthcare Excellence Awards 2014. Dr Bishnu Panigrahi, Head-MSOG was named the Healthcare Personality of the Year (Delhi-NCR). Dr Sanjeev Gulati, Additional Director-Nephrology, Fortis Flt Lt Rajan Dhall Hospital, Vasant Kunj, New Delhi, was named the Healthcare Personality of the Year (Nephrology). Dr Praveen Gupta, Director and HOD-Neurology, Fortis Memorial Research Institute, Gurgaon, was honoured for delivering Outstanding Services For Neurology (North India). Dietician Seema Singh from Fortis Flt Lt Rajan Dhall Hospital, Vasant Kunj, New Delhi, was recognised as the Best Dietician of The Year (North India) and Dr Neeraj Sanduja, Senior Consultant - Ophthalmology, Fortis Memorial Research Institute, Gurgaon, was acknowledged as the Best Ophthalmologist in Delhi/NCR.

- Dr Atul N.C. Peters, Director – Bariatric & Metabolic Surgery, Fortis Hospital, Shalimar Bagh, New Delhi, received accreditation as a Surgeon of Excellence for Metabolic & Bariatric Surgery from the Surgical Review Corporation, USA. He was feted by the Limca Book of Records for setting a National Record of performing 16 bariatric surgeries in a single day.

Other significant awards

- Chief People Officer Mr Rajiv Kapoor was hailed as one of the '100 Most Talented Global HR Leaders' by CHRO Asia in association with the World HRD Congress. The New Delhi Institute of Management, too, conferred the coveted Business Excellence & Innovative Best Practices Award 2015 upon Mr Kapoor for his inspiring leadership.

- Mr Vikram Goel and Ms Rajwinder Kaur from the Biomedical Department of Fortis Hospital, Mohali, won the First Prize worth Rs 5 lakh at the prestigious Intel Embedded Challenge, 2014, for their invention, the "Catheter Reprocessing System (CRS)."

About Fortis Healthcare Limited

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care speciality facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 54 healthcare facilities (including projects under development), approximately 10,000 potential beds and 260 diagnostic centres.

For further details please contact:

Raghu Kochar / Nibha Bhandari Vyas
Fortis Healthcare Ltd
9811617256 / 98110 65557

Anurag Kalra / Gaurav Chugh
Fortis Healthcare Ltd
9810109253 / 9958588900